We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Allovir Inc
5 own
4 watching
Current Price
$5.75
$-0.22
(-3.69%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
532.68M
52-Week High
10.29
52-Week Low
3.17
Average Volume
0.18M
Dividend Yield
--
P/E Ratio
--
Market Capitalization532.68M52-Week High10.2952-Week Low3.17Average Volume0.18MDividend Yield--P/E Ratio--What does the Allovir Inc do?
We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. --- We were formed in August 2013 under the laws of the state of Delaware under the name AdCyte LLC. In July 2014, we changed our name to ViraCyte LLC. In September 2018, we converted from a Delaware limited liability company to a Delaware corporation and changed our name to ViraCyte, Inc. In May 2019, we changed our name to AlloVir, Inc. Our principal executive offices are located at 139 Main Street, Suite 500, Cambridge, MA 02142, and our phone number is 617-433-2605. We have three wholly-owned subsidiaries, AlloVir International Designated Activity Company, AlloVir Securities Corporation and AlloVir Italia S.R.L., each of which was formed in 2019. Our website address is www.AlloVir.com.
Read More
How much money does Allovir Inc make?
News & Events about Allovir Inc.
Business Wire
20days ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced the companys 2023 priorities and anticipated future milestones across its pipeline of virus-specific T cell therapies, including its lead investigational therapy posoleucel. These updates...
Business Wire
2 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that final data from the Phase 2 study of posoleucel for the prevention of clinically significant infections or diseases by multiple viruses following allogeneic hematopoietic cell...
Business Wire
7 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK...
Ticker Report
9 months ago
Shares of AlloVir, Inc. (NASDAQ:ALVR Get Rating) gapped up before the market opened on Wednesday . The stock had previously closed at $5.41, but opened at $7.29. AlloVir shares last traded at $8.25, with a volume of 885,061 shares trading hands. Several equities analysts recently issued ...
PR Newswire
9 months ago
Thinking about buying stock in Allovir, Sono Group, Ion Geophysical, Toughbuilt, or Snowflake? Thinking about buying stock in Allovir, Sono Group, Ion Geophysical, Toughbuilt, or Snowflake? PR Newswire NEW YORK, April 20, 2022 NEW YORK, April 20, 2022 /PRNewswire/ -- InvestorsObserver issues...
Frequently Asked Questions
Frequently Asked Questions
What is Allovir Inc share price today?
Can Indians buy Allovir Inc shares?
How can I buy Allovir Inc shares from India?
Can Fractional shares of Allovir Inc be purchased?
What are the documents required to start investing in Allovir Inc stocks?
What is today’s traded volume of Allovir Inc?
What is today’s market capitalisation of Allovir Inc?
What is the 52-Week High and Low Range of Allovir Inc?
What percentage is Allovir Inc down from its 52-Week High?
What percentage is Allovir Inc up from its 52-Week Low?
Current Price
$5.75
$-0.22
(-3.69%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.